Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Rhea-AI Summary
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech developing immunotherapies for KRAS-driven cancers, has been added to the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026, following the 2026 Russell reconstitution.
The company views this as a milestone that broadens visibility with institutional investors as it advances its ELI-002 7P program.
Positive
- Added to Russell 2000 and Russell 3000 indexes effective June 26, 2026
- Index inclusion expected to broaden visibility with institutional investors
- Milestone supports ongoing advancement of ELI-002 7P cancer immunotherapy program
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 17 | Clinical observations | Positive | +70.7% | Reported three metastatic pancreatic cancer patients achieving complete responses after follow-on therapy. |
| Jun 15 | Phase 2 results | Negative | -72.5% | Phase 2 AMPLIFY-7P trial failed primary DFS endpoint in intent-to-treat population. |
| Jun 1 | Preclinical data | Positive | +5.9% | Peer-reviewed publication showed potent, durable immune responses with AMP-DNA adjuvant platform. |
| May 11 | Earnings update | Neutral | -9.1% | Reported Q1 2026 financials and cash runway guidance into Q4 2026. |
| Apr 30 | Conference appearance | Neutral | +2.9% | Announced upcoming presentation at a major healthcare conference with company leadership. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ELTX news has triggered sharp, directionally consistent moves around major clinical updates, with more modest, mixed reactions to routine corporate news.
Key Terms
russell 2000 financial
russell 3000 financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution.
“Inclusion of Elicio Therapeutics in the Russell 2000® and Russell 3000® Indexes is a meaningful milestone that reflects the growing recognition of the Company’s progress,” said Robert Connelly, Chief Executive Officer of Elicio Therapeutics. “As we continue to advance our ELI-002 7P program forward, this inclusion broadens our visibility with institutional investors and underscores our ongoing commitment to delivering meaningful value for patients and shareholders.”
The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index, a subset of the Russell 3000®, measures the performance of small-cap stocks and represents approximately
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
For further information on the Russell indexes, please visit the FTSE Russell website.
About ELI-002
Elicio’s lead product candidate, ELI-002, is a structurally novel investigational AMP cancer immunotherapy that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio’s proprietary AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration.
ELI-002 7P (7-peptide formulation) was evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with mKRAS-driven pancreatic cancer (NCT05726864). The Phase 2 AMPLIFY-7P trial included patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. Based on topline results and post-hoc analyses, Elicio has refined its Phase 3 development strategy to focus on patients with lower residual disease burden and extended treatment duration. Elicio intends to initiate a Phase 1 study in metastatic PDAC designed to provide a rapid assessment of clinical activity through a focused, confirmatory study, subject to funding. Elicio plans to use the study findings to further evaluate checkpoint inhibitor combinations and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial. At the time of the Phase 2 AMPLIFY-7P analysis, data for overall survival remained immature. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately
Cautionary Note on Forward-Looking Statements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding Elicio’s planned clinical programs, including the timing and outcome of planned clinical trials; the potential of Elicio’s product candidates, including the potential of ELI-002 7P; the potential for future expansion of ELI-002 to other indications, including in mKRAS positive lung cancer and other mKRAS positive cancers; the potential benefits and effectiveness of off-the-shelf immunotherapy approaches; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Elicio uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on Elicio’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s plans to develop and commercialize its product candidates, including ELI-002 7P; the timing of initiation of Elicio’s planned clinical trials; the timing of the availability of data from Elicio’s clinical trials; the timing of any planned investigational new drug application or new drug application; Elicio’s plans to research, develop and commercialize its current and future product candidates; and Elicio’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.
New factors emerge from time to time, and it is not possible for Elicio to predict all such factors, nor can Elicio assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed under the heading “Risk Factors” in Elicio’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, as updated by subsequent reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.
Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
Media Contact
Michael Fitzhugh
LifeSci Communications
(415) 269-7757
mfitzhugh@lifescicomms.com
